Companies: 10,795·Total market cap: $144.5T
Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc

BDRXNASDAQHealthcare● Active
$3.26
$-0.10(-2.98%)
Market Cap$546888
P/E Ratio—
52W High$66.5
52W Low$2.86
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Biodexa Pharmaceuticals Plc (BDRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001643918 · BDRX · NASDAQ · as of Jun 8, 2026

Filing snapshot

673
Total Filings
SCHEDULE 13G/A
Latest Form
2026-05-15
Most Recent
2015
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001643918 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-27
Fiscal Year End
Mar 27, 2026
Accession No.
0001214659-26-003921
Primary Document
bp31726520f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001643918 · Accession 0001214659-26-003921

Latest Key Filings

6-KQuarterly Report
Quarterly Report
2026-05-14
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
6-KCurrent Report (Foreign Issuer)
Current Report (Foreign Issuer)
2026-05-14
View
424B3424B3
424B3
2026-04-02
View
424B3424B3
424B3
2026-04-02
View
424B3424B3
424B3
2026-04-02
View
424B3424B3
424B3
2026-04-02
View
424B3424B3
424B3
2026-04-02
View
424B3424B3
424B3
2026-04-02
View
EFFECTEFFECT
EFFECT
2026-03-30
View
EFFECTEFFECT
EFFECT
2026-03-30
View
EFFECTEFFECT
EFFECT
2026-03-30
View
EFFECTEFFECT
EFFECT
2026-03-30
View
EFFECTEFFECT
EFFECT
2026-03-30
View
EFFECTEFFECT
EFFECT
2026-03-30
View
POS AMPOS AM
AMENDMENT NO. 2
2026-03-30
View
Showing 1–15 of 673 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001643918  |  Exchange: NASDAQ · Healthcare

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) has submitted 673 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001643918, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Biodexa Pharmaceuticals Plc's most comprehensive regulatory disclosure. The most recent Biodexa Pharmaceuticals Plc 10-K was filed on 2026-03-27 for fiscal year ending 2026. Historical BDRX 10-K annual reports are available from 2015 through 2026.

Investors researching Biodexa Pharmaceuticals Plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
ESLA SEC Filings →KZIA SEC Filings →BIVI SEC Filings →CNSP SEC Filings →INM SEC Filings →CANF SEC Filings →GLMD SEC Filings →GNPX SEC Filings →
→ BDRX Financials→ BDRX Earnings→ BDRX Insider Trades

Frequently Asked Questions

BDRX SEC Filings · 8 questions

Biodexa Pharmaceuticals Plc (BDRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 673 filings and access original documents at no cost. Biodexa Pharmaceuticals Plc's CIK is 0001643918.

BDRX SEC filingsBiodexa Pharmaceuticals Plc SEC documentsfind BDRX 10-K